Impact Biomedical Inc.
IBO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001834105
In the last 90 days, Impact Biomedical Inc. insiders filed 0 open-market purchases and 1 sale; 23 institutions reported holding it in 13F filings for Q2 2026, worth $1.76M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Impact Biomedical Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +1 vs. Q3 2024
- Shares held
- 89.1K
- +23.0K (+34.9%) vs. Q3 2024
- Total value
- $76.1K
- +$16.8K (+28.3%) vs. Q3 2024
- New holders
- 5
- 1 more added
- Sold out
- 4
- 1 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IBO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $1.76M |
| Q1 2026 | 21 | $2.23M |
| Q4 2025 | 24 | $726.3K |
| Q3 2025 | 21 | $357.8K |
| Q2 2025 | 20 | $328.2K |
| Q1 2025 | 17 | $335.4K |
| Q4 2024 | 11 | $76.1K |
| Q3 2024 | 10 | $59.3K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Impact Biomedical Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 20,774 | $30.1K | 0.00% | +20,774 | New |
| FNY Investment Advisers, LLC | 12,600 | $18.0K | 0.01% | +12,600 | New |
| State Street Corp | 11,171 | $16.2K | 0.00% | +11,171 | New |
| UBS Group AG | 4,252 | $6.17K | 0.00% | +4,249+141,633.3% | Added |
| Tower Research Capital LLC (TRC) | 3,760 | $5.45K | 0.00% | +3,760 | New |
| Newbridge Financial Services Group, Inc. | 86 | $125 | 0.00% | +86 | New |
| Wells Fargo & Company | 29 | $42 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 17 | $24 | 0.00% | −2,579−99.3% | Reduced |
| Danske Bank A/S | 3 | $4 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Ferguson Wellman Capital Management, Inc | 36,364 | $0 | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −13,361−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −12,502−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −1,120−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −58−100.0% | Sold out |